Results 81 to 90 of about 17,734 (168)

Perbandingan Efek Curcumin, Dacarbazine dan Kombinasinya terhadap Ekspresi Caspase-9 pada Kultur Sel Melanoma Maligna

open access: yes, 2012
Tujuan: Mengetahui perbedaan efektifitas antara pemberian curcumin , dacarbazine dan kombinasinya terhadap ekspresi caspase-9 pada kultur sel melanoma maligna ( cell line CRL 1872).
Mardalena, Eva
core  

Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes

open access: yesClinicoEconomics and Outcomes Research, 2018
EJ Gibson,1 N Begum,1 I Koblbauer,1 G Dranitsaris,2 D Liew,3 P McEwan,4 AA Tahami Monfared,5,6 Y Yuan,7 A Juarez-Garcia,7 D Tyas,8 M Lees9 1Wickenstones Ltd, Didcot, UK; 2Augmentium Pharma Consulting Inc, Toronto, ON, Canada; 3Department of Epidemiology ...
Gibson EJ   +10 more
doaj  

Inflammation-associated signal pathways activation during drug resistance development in cancer cells

open access: yesActa Biomedica Scientifica
Background. Cancer drug resistance represents an obvious problem in clinical oncology. Among various intracellular pathways activated during drug resistance development, proinflammatory cascades considered to be involved as well. The inflammatory process
E. Z. Lapkina   +4 more
doaj   +1 more source

PRIMARY MALIGNANT MELANOMA UTERINE CERVIX

open access: yesJournal of Cancer and Allied Specialties, 2016
A 40-year-old premenopausal female presented with foul-smelling per vaginal discharge for 3 months. Diagnostic work revealed a locally advanced primary malignant melanoma of uterine cervix.
Asghar H Asghar   +5 more
doaj   +1 more source

Dacarbazine in solitary fibrous tumor : a case series analysis and preclinical evidence vis-à-vis temozolomide and antiangiogenics

open access: yes, 2013
Purpose: To explore the value of triazines in solitary fibrous tumor (SFT). Experimental Design: We retrospectively reviewed 8 cases of patients with SFT treated with dacarbazine (1,200mg/m2 every 3 weeks) as from January 2012.
S. Stacchiotti   +13 more
core   +1 more source

Validation of the advanced‐stage Hodgkin lymphoma international prognostic index (A‐HIPI) in the GHSG HD21 trial

open access: yes
HemaSphere, Volume 10, Issue 9, September 2026.
Hishan Tharmaseelan   +16 more
wiley   +1 more source

Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma

open access: yes, 1999
PURPOSE: Several single-institution phase II trials have reported that the Dartmouth regimen (dacarbazine, cisplatin, carmustine, and tamoxifen) can induce major tumor responses in 40% to 50% of stage IV melanoma patients.
Paul B. Chapman   +11 more
core   +1 more source

Post-treatment de-phosphorylation of p53 correlates with dasatinib responsiveness in malignant melanoma

open access: yesBMC Cell Biology, 2018
Background Dasatinib (Sprycel) was developed as a tyrosine kinase inhibitor targeting Bcr-Abl and the family of Src kinases. Dasatinib is commonly used for the treatment of acute lymphoblastic and chronic myelogenous leukemia.
Josip Skoko   +4 more
doaj   +1 more source

Melanogenesis inhibition by (2-Methylbutyryl) Shikonin, a naturally occurring naphthoquinone potentiates dacarbazine anti-melanoma efficacy via ROS mediated apoptotic pathway

open access: yesPharmacological Research - Modern Chinese Medicine
Introduction: Melanoma is a highly aggressive skin cancer with strong metastatic potential and resistance to conventional chemotherapy. Dacarbazine (DTIC) is widely used for melanoma treatment, but its effectiveness is often compromised by acquired ...
Aalim Maqsood Bhat   +2 more
doaj   +1 more source

In vitro functionality and toxicity of dacarbazine delivery nanosystem for melanoma. [PDF]

open access: yes, 2018
Dacarbazine (Dac) is a chemotherapeutic for melanoma. Its poor solubility, short half-life, and side effects limit its therapeutic use. Nanoparticles used as drug delivery systems (DDS) improve drug pharmacological properties, target site concentration ...
Almoussalam, Mousallam Mohammad
core   +2 more sources

Home - About - Disclaimer - Privacy